Page 2 - Robert Stott News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The ACG and the AGA Gastrointestinal Opportunity Fund have made “strategic” financial investments in Oshi Health to quicken the adoption of a whole-person multidisciplinary hybrid care model for digestive health, according to a release.The collaboration between ACG, AGA and Oshi Health will allow for GI practices to offer dietary and behavioral health interventions based on guideline

The FDA has approved Bylvay for the treatment of cholestatic pruritus due to Alagille syndrome in patients aged 12 months or older, according to an Ipsen Biopharmaceuticals press release.This approval marks the second rare cholestatic liver disease indication for Bylvay (odevixibat, Ipsen/Albiero Pharmaceuticals), a non-systemic ileal bile acid transport inhibitor originally approved in 2021 for

The FDA has approved Linzess, the first oral therapy for pediatric functional constipation in patients aged 6 to 17 years, according to an agency release. Previously approved for the treatment of adults with irritable bowel syndrome with constipation or chronic idiopathic constipation, the new drug application for Linzess (linaclotide 72 mcg, AbbVie/Ironwood) was assigned a Prescription Drug User

UnitedHealthcare recently announced that beginning June 1, 2023, commercial plan members will be required to obtain prior authorization for gastroenterology endoscopy services. By far the largest health insurance company in the United States, UnitedHealthcare generates more than $286 billion in total revenue — more than double that of the next closest competition, Anthem —and serves

The FDA has approved Celltrion USA’s Yuflyma as the ninth biosimilar to adalimumab for all eligible indications of the reference product, and the latest in a flood of biosimilars cleared for 2023 release in the United States.Yuflyma (adalimumab-aaty, Celltrion USA) is a high-concentration (100 mg/mL), citrate-free biosimilar to the world’s top-selling Humira (adalimumab, AbbVie),